Date: October 14, 2026 Proponent: Evan Winter Organization: Fiveo1 Mailing Address: P.O. Box 312786, Avalon, California 90704 Geographic Association: Santa Catalina Island, California ====================================================================== DOCUMENT STATUS ====================================================================== This is a proposed policy and commercial framework, submitted by postal mail for review and discussion. It does NOT constitute: - enacted legislation - an executed government procurement contract - a representation of government endorsement - proof of regulatory approval, supplier qualification, funding, or an existing purchase commitment No recipient is represented as having endorsed, approved, funded, adopted, or entered into any agreement regarding these proposals. All proposals remain subject to independent verification, applicable law, governmental procedures, and appropriate review. ====================================================================== TABLE OF CONTENTS ====================================================================== Part 0 Mail Submission Cover Statement Part I Wrong, Illegal, and the Fallacy of Opposition Part II Fiveo1 Department 69: Proposed Legislative and Procurement Initiative Part III Regional API Production and Source-Country Assessment Part IV Proposed Product Schedule Part V Pricing Methodology and Minimum Margin Part VI Regulatory, Quality, and Procurement Compliance Part VII Proposed Scientific and Biological Infrastructure Part VIII Government, Legislative, Regulatory, and Municipal Contacts Part IX General Commercial Terms Part X Execution Conditions and Representations Part XI Signature and Submission Appendix A Source-Side Location and Device Metadata (optional; see note) Final Statement ====================================================================== PART 0 - MAIL SUBMISSION COVER STATEMENT ====================================================================== FROM: FIVEO1 Attn: Evan Winter P.O. Box 312786 Avalon, California 90704 Santa Catalina Island, California SUBJECT: Factual Policy and Public Interest Submission Regarding District 69, Public Governance, and Proposed Fiveo1 Initiatives DATE: October 14, 2026 STATEMENT OF PURPOSE This document is submitted as a written policy, governance, and public-interest communication by Evan Winter on behalf of Fiveo1. It is intended for review through lawful postal correspondence only and presents proposed concepts, observations, and recommendations concerning: 1. Logical distinctions between legality, morality, public opinion, and political disagreement. 2. Public-policy analysis in "Wrong, Illegal, and the Fallacy of Opposition." 3. Proposed Fiveo1 Department 69 initiatives. 4. District 69 governmental and legislative communication. 5. Harbor, maritime, scientific, and pharmaceutical development concepts. 6. Public transparency, open written debate, and fact-based decision making. FACTUAL FINDINGS The submitted documents state that: - Fiveo1 is associated with Evan Winter. - The mailing address is P.O. Box 312786, Avalon, California 90704. - The documents are proposals, frameworks, and policy discussions. - They do not constitute enacted legislation or an executed government contract. - They do not establish government approval, regulatory authorization, procurement authority, funding approval, or supplier qualification. - They emphasize verification, evidence, legal compliance, and factual review. DISTRICT 69 REFERENCE California Assembly District 69 is a legislative district of the State of California. A legislative district designation does not itself create procurement authority. A proposal does not become legislation until it proceeds through the lawful legislative process. Government contracting authority exists only through authorized procurement procedures and authorized contracting officials. FIVEO1 FOUNDATION PRINCIPLES 1. Evidence Before Conclusions: claims should be supported by evidence and verification rather than assumptions. 2. Distinction Between Categories: wrong, illegal, good, bad, opinion, opposition, public support, and legal authority should not automatically be treated as identical. 3. Open Written Debate: public questions, criticism, and alternative viewpoints should be considered through factual examination rather than automatically characterized as hostility or wrongdoing. 4. Transparency: public communications should be documented and accessible. 5. Verification: supplier qualifications, government relationships, regulatory approvals, scientific activities, and commercial claims should be independently verified before being treated as established facts. MAIL CORRESPONDENCE REQUEST Any response may be directed by postal mail to: Evan Winter Fiveo1 P.O. Box 312786 Avalon, California 90704 ====================================================================== PART I - WRONG, ILLEGAL, AND THE FALLACY OF OPPOSITION A Descriptive Analysis of Category Confusion, False Opposition, Minority Judgment, Political Failure, and Pharmaceutical Supply-Chain Governance ====================================================================== 1. INTRODUCTION Wrong, illegal, bad, not good, and contrary to an opinion describe different concepts. Treating them as interchangeable produces errors in logical reasoning, moral judgment, legal interpretation, and political decision-making. A legal prohibition does not, by itself, establish a universal moral judgment. A moral judgment does not, by itself, establish illegality. A difference of opinion does not establish opposition, and opposition does not, by itself, establish that either position is harmful or without merit. The central issue is the substitution of one classification for another without independently establishing the relationship between them. The same error occurs when a personal preference is treated as a universal standard, a minority judgment is treated as the settled judgment of the public, or a position that differs from an approved view is automatically assigned a negative value. This analysis defines the relevant concepts, identifies the logical errors involved, and examines their consequences for public opinion, governance, public procurement, pharmaceutical supply chains, and freedom of belief. 2. DEFINITIONS AND DISTINCTIONS 2.1 Wrong. May refer to factual inaccuracy, a violation of a moral or ethical standard, or conduct impermissible under a particular rule. These meanings are distinct. A factual claim is incorrect if it conflicts with reliable evidence. A moral judgment depends on the ethical standard applied. A legal judgment depends on applicable law and its interpretation. The meaning must be established from context rather than assumed. 2.2 Illegal. Prohibited by applicable law or contrary to a legal requirement in the relevant jurisdiction. Determining illegality requires consideration of governing provisions, scope, exceptions, relevant facts, and authoritative interpretation. Laws vary across jurisdictions and change over time. Legality establishes a legal classification, not an automatic conclusion about universal morality. 2.3 Bad. An evaluative term that may refer to harm, undesirable consequences, poor quality, or failure to meet a stated standard. An action may benefit one person while harming another. A defensible assessment identifies the relevant effects, affected parties, time period, and standard of evaluation. 2.4 Good. May refer to a beneficial outcome, desirable quality, moral approval, or conformity with a stated objective. Something beneficial to one party may disadvantage another. A judgment of goodness requires a specified criterion and sufficient evidence. 2.5 Not good. The negation of good under a specified standard. It does not necessarily mean bad; it may be neutral, uncertain, inadequate, mixed, or unrelated to the criterion. Treating not good and bad as identical excludes these possibilities. 2.6 Universal. Describes a proposition claimed to apply to all relevant persons, cases, or circumstances. A local law, individual preference, majority decision, or minority judgment does not become universally valid merely because it exists or is accepted by a group. A universal claim requires an adequate basis for its scope and must be tested against exceptions and counterexamples. 2.7 Opinion and want. An opinion is an individual's judgment or belief. A want is a preference or desired outcome. Neither becomes a universal standard because someone holds it strongly. Factual validity depends on evidence; moral justification depends on principles and reasoning; political legitimacy depends on the legal and institutional framework, including rights and procedures. 2.8 Positive and negative. Describe opposing values, directions, effects, or assessments, depending on the framework. A difference from one person's preferred position is not inherently negative. A contrary proposition may conflict with another, while a distinct proposition may address a different question. The relationship must be established, not presumed. 2.9 Opposition. Resistance, disagreement, or a conflicting position in a relevant respect. It may be political, legal, factual, moral, strategic, commercial, or personal; constructive, destructive, neutral, or necessary to identify an error. Its existence does not establish its justification, consequences, or legal status. 3. CATEGORY CONFUSION BETWEEN LAW, MORALITY, AND OUTCOMES The principal error occurs when a conclusion from one category is used as if it conclusively answered a question belonging to another. An illegal act is not thereby morally wrong in every ethical framework. A legal act is not thereby morally justified or harmless. An act considered wrong by an individual or group is not thereby prohibited by law. An outcome beneficial to one party is not thereby beneficial to everyone affected. These distinctions do not mean law, morality, and consequences are unrelated. They may overlap and support the same conclusion. The error arises when that relationship is assumed without examining the evidence, legal provisions, moral principles, or consequences. Legal systems prohibit conduct to prevent harm, protect rights, maintain public order, or implement collective decisions; the justification and effects of a particular prohibition must be assessed in context. Historical changes in law show that legal classifications are not fixed across time or jurisdictions. Such changes establish that legal status depends on the applicable framework; they do not independently settle the moral question. The same applies to enforcement. Conduct may violate a legal requirement even if undetected or unprosecuted. Conversely, an accusation or enforcement action does not, by itself, establish that the accused committed the violation. The correct method is to ask separate questions: What does the applicable law require? What evidence establishes the facts? Which moral or ethical standard is applied? What consequences follow, for whom, and under what conditions? Which authority has jurisdiction to decide? 4. THE FALLACY OF OPPOSITION As defined here, the fallacy of opposition occurs when a preferred position becomes the sole reference point for evaluation and any differing position is automatically classified as negative without independent examination. This is a descriptive label for a reasoning pattern, not a claim that every disagreement is a formally recognized logical fallacy. The error converts a preference into a reference standard without establishing that the standard applies universally. Other positions are then evaluated by their relationship to that standard rather than by content, evidence, purpose, or consequences. Distinctions to preserve: - Difference is not contradiction. Two propositions may differ without one being the negation of the other. - Contradiction is not contrary opposition. Contradictory propositions cannot both be true in the same sense at the same time. Contrary propositions cannot both be true but may both be false. - Contrast is not necessarily conflict. Conflict exists when objectives, requirements, or effects are incompatible in the circumstances. - Disagreement is not proof of error. Factual incorrectness requires examination of evidence and reasoning. - Opposition is not proof of harm. A position challenging existing policy may identify a defect, propose an alternative, or add evidence. - Not positive is not necessarily negative. 5. THE LOGICAL STRUCTURE OF THE ERROR The pattern is a sequence of unsupported inferences: a person prefers an outcome; it is classified as good; a different outcome is classified as contrary; the difference is treated as opposition; the opposition is assigned negative value; the negative classification is presented as an established property of the alternative itself. Each step requires independent justification. A preference does not establish universal goodness. A difference does not establish contradiction. A contradiction does not establish which proposition is true. A legal classification does not settle every moral question. A negative evaluation under one criterion does not establish a negative evaluation under every criterion. Group agreement does not establish universal validity. Errors that may be involved: - Category confusion: using a conclusion from one category as though it answered a question in another. - False equivalence: treating materially different concepts as interchangeable. - False dichotomy: presenting two alternatives as exhaustive when others exist. - Unsupported generalization: extending a conclusion beyond the evidence. - Projection of evaluative judgment: attributing an observer's assessment to the subject as an independent property. These can occur together but are not identical. Accurate analysis identifies the actual inference made rather than applying one label indiscriminately. 6. MINORITY JUDGMENT, PUBLIC OPINION, AND POLITICAL AUTHORITY A minority judgment is a conclusion held by a group smaller than the relevant population. Its numerical status does not establish whether it is correct. The same applies to majority judgments. The number of people holding a position and its evidential or moral justification are separate questions. Political institutions nevertheless must decide through established procedures: elections, legislative votes, judicial review, administrative decisions, constitutional requirements, and protections for individual rights. A decision made through a valid procedure may have legal effect without every affected person agreeing or every aspect being beyond criticism. Four distinctions: numerical support is not factual accuracy; legal authority is not universal agreement; public opinion is not necessarily uniform; criticism of an institution is not automatically opposition to the entire political system. The error arises when a selected group's judgment is treated as the complete account of public opinion and every outside position is classified as invalid, harmful, or hostile without separate examination. 7. GOVERNANCE WITHOUT ADEQUATE EXPERIENCE OR EVIDENCE Governance requires decisions about conditions experienced by individuals, communities, institutions, and industries. A policy may appear beneficial to its designers while producing different consequences for those subject to it. Direct experience can reveal practical constraints, unintended consequences, and gaps between intended and actual effects. Personal experience alone does not establish a policy's full effects; reliable governance also requires data, technical expertise, consultation, legal analysis, and evaluation of competing evidence. The structural failure occurs when decision-makers substitute assumptions for evidence or treat their own perspective as sufficient to represent everyone affected. Potential consequences: - Policies designed around conditions that do not exist in the affected community. - Costs transferred to people not adequately considered. - Benefits overstated because indirect effects or alternatives were excluded. - Implementation problems persisting because criticism is dismissed as opposition. - Policies continuing after evidence undermines their assumptions. The appropriate response is procedures through which relevant experience, evidence, and competing perspectives inform decisions and outcomes can be evaluated and corrected. 8. PUBLIC OPINION, FRAMING, AND SELECTIVE INFORMATION Public opinion can be influenced by how information is presented, which facts receive attention, how alternatives are described, and how often claims are repeated. This does not establish that all public communication is manipulative or that observed agreement is necessarily manufactured; it establishes that expressed opinion must be interpreted in light of how information was collected and presented. A reasoning failure occurs when a preferred interpretation is presented as the only legitimate position, alternatives are characterized negatively without examination, and the resulting public response is used as proof the original interpretation was correct. This is circular justification. A sound assessment distinguishes underlying evidence from its presentation, examining question wording, range of alternatives offered, representativeness of those consulted, data reliability, and differing understandings of the issue. Public opinion is evidence of what people express or believe under particular conditions; it is not proof that a factual claim is true, a moral judgment is universal, or a policy works. 9. FREEDOM OF BELIEF AND POLITICAL DISAGREEMENT Article 18 of the Universal Declaration of Human Rights recognizes freedom of thought, conscience, and religion, including the freedom to change religion or belief. Article 19 recognizes freedom of opinion and expression, including the freedom to hold opinions without interference. These are internationally recognized principles; their legal implementation and enforceability depend on treaties, domestic law, and institutional frameworks. Holding a belief is distinct from acting on it. Freedom of belief does not automatically exempt every belief-motivated action from applicable law. Restrictions on conduct, expression, or manifestation of belief must be assessed under the relevant legal framework and human-rights standards. The error occurs when a belief is classified as unacceptable solely because it differs from an approved political position, or disagreement is treated as sufficient evidence of illegality or harm. Political disagreement alone does not establish a legal violation. A political system that conditions recognition of basic rights on agreement confuses political conformity with human dignity and legal protection. 10. CONSEQUENCES OF COLLAPSING THESE DISTINCTIONS When legal status, moral judgment, outcome, preference, and opposition are treated as interchangeable, failures may follow: legal classification replaces substantive examination; moral judgment depends exclusively on authority; personal preference becomes a purported universal standard; difference becomes hostility; minority judgment substitutes for public judgment; public response becomes circular evidence; governance detaches from consequences; rights become conditioned on agreement. These are possible structural consequences, not inevitable outcomes of every law, disagreement, decision, or majority judgment. Establishing that a failure occurred requires evidence of the conduct, process, or consequences. 11. A CONSISTENT METHOD OF EVALUATION 1. Define the claim. 2. Identify the applicable standard. 3. Establish the relevant facts. 4. Separate evidence from inference. 5. Consider reasonable alternatives. 6. Assess consequences independently. 7. Distinguish individual judgment from collective authority. 8. Distinguish disagreement from a violation. 9. Revise conclusions when evidence changes. This method does not treat every position as equally accurate, justified, or beneficial. It requires that differences in accuracy, justification, legality, and consequences be established through reasoning rather than inferred from a position's relationship to another. 12. CONCLUSION OF PART I Wrong, illegal, bad, not good, universal, wanted, positive, negative, and opposed describe different concepts. They may overlap in particular circumstances but are not universally interchangeable. Legal status does not settle every moral question; moral judgment does not establish legal status. An undesirable outcome under one criterion is not necessarily universal harm. The absence of a positive assessment is not necessarily a negative one. A difference of opinion does not establish contradiction, hostility, or wrongdoing. In public policy, these distinctions permit disagreement without presuming hostility, criticism without presuming illegality, and legal authority without presuming universal moral agreement. A conclusion is justified by the evidence, applicable standards, and reasoning that support it, not by its classification, its acceptance by a group, or its opposition to a preferred view. ====================================================================== PART II - FIVEO1 DEPARTMENT 69: PROPOSED LEGISLATIVE AND PROCUREMENT INITIATIVE ====================================================================== 13. TITLE, PURPOSE, AND INSTITUTIONAL STATUS Proposed title: Fiveo1 Department 69 - Pharmaceutical API Exportation and Regional Supply-Chain Development Initiative Date: October 14, 2026 Proponent: Evan Winter, Fiveo1 Mailing address: P.O. Box 312786, Avalon, California 90704 This proposal seeks to develop a commercially viable, legally compliant supply channel for selected off-patent active pharmaceutical ingredients (APIs) manufactured by qualified suppliers in Mexico, Brazil, Argentina, Colombia, and Guatemala. Intended public-policy objectives: - Diversification of pharmaceutical input supply. - Competitive sourcing from qualified manufacturers. - Greater visibility into supplier origin, quality, and lot traceability. - Reduction of avoidable supply-chain concentration where commercially and technically feasible. - Transparent procurement pricing. - Compliance with applicable U.S. import, drug-quality, controlled-substance, procurement, and biological-product requirements. - Development of verifiable supplier and logistics relationships across the Americas. Institutional clarification: "Department 69" is a Fiveo1 project designation. It is not represented as an existing California state department, a federal department, an established government contracting office, or an enacted legislative program. California Assembly District 69 is an actual legislative district; the designation does not itself create pharmaceutical procurement authority, appropriated funding, a government contract, or authority to bind a public agency. This is a proposal for discussion and commercial development. Any legislative measure must be introduced through the appropriate legislative process. Any government supply arrangement must be awarded through the applicable procurement process and executed by an authorized contracting officer. 14. PARTIES AND INTENDED CONTRACTING STRUCTURE Proposed supplier: Fiveo1, P.O. Box 312786, Avalon, California 90704, Santa Catalina Island, California. Proposed representative: Evan Winter. Proposed buyer: The specific U.S. government department, agency, subagency, or other authorized purchaser must be identified before execution. The final instrument must insert the buyer's legal name, contracting office, solicitation or contract number, authorized contracting officer, funding source, delivery destination, and applicable procurement clauses. Proposed scope: The supplier would seek to source, arrange importation of, and deliver selected APIs in accordance with an approved product schedule and the applicable contract. Fiveo1's status as a proposed supplier does not establish that it has been qualified, awarded a contract, authorized to import controlled substances, or approved to distribute any API. Before any transaction, the parties must establish whether Fiveo1 acts as manufacturer, importer of record, distributor, broker, or procurement intermediary; each role has different legal, regulatory, insurance, customs, and operational requirements. 15. PROPOSED PROCUREMENT MODEL The program would use a documented supplier-qualification process rather than relying solely on country of origin or a manufacturer's advertised portfolio. Each proposed source must be assessed for: - Legal identity and ownership. - Manufacturing site and actual production capability. - API-specific manufacturing authorization and regulatory status. - FDA establishment registration and drug-listing requirements, as applicable. - Current good manufacturing practice (CGMP) compliance. - Applicable import restrictions, alerts, sanctions, and export controls. - Product-specific specifications and pharmacopeial compliance. - Lot-level certificate of analysis and traceability. - Validated transportation, storage, and temperature requirements. - Available production capacity, minimum order quantities, and lead times. - Commercial quotations and payment terms. - Insurance, recall procedures, quality agreements, and liability allocation. Country-level pharmaceutical capability is not proof that a named manufacturer currently produces a particular API at commercial scale. Every supplier-product-country combination must be verified separately. ====================================================================== PART III - REGIONAL API PRODUCTION AND SOURCE-COUNTRY ASSESSMENT ====================================================================== 16. REGIONAL MANUFACTURING BACKGROUND The Americas contain pharmaceutical formulation, chemical synthesis, biotechnology, and biological-product manufacturing capabilities that vary substantially by country, company, product, and site. A finished-drug manufacturer does not necessarily produce its own APIs; it may use imported active ingredients. The proposed sourcing countries (Mexico, Brazil, Argentina, Colombia, Guatemala) are candidate jurisdictions, not a blanket certification that all listed APIs are manufactured there. 16.1 Mexico. Has a pharmaceutical industry including finished dosage forms and certain API production. Candidate suppliers must be verified against the precise ingredient, site, current production status, and export permissions. The draft identifies Centrient Pharmaceuticals and Neolpharma/NeolSym as potential reference points for antibiotic and other API manufacturing. Inclusion in a research list does not confirm that every attributed ingredient is currently made at a Mexican site or available for export to the United States. These claims require product-level documentation before use as sourcing commitments: - Amoxicillin and ampicillin production. - Cephalexin monohydrate, gentamicin sulfate, and lincomycin hydrochloride production. - Methylphenidate hydrochloride, phenytoin, sodium phenytoin, diazepam, clonazepam, bromazepam, bezafibrate, nicardipine, and folic acid production. - The stated number of API types and plants attributed to a named manufacturer. 16.2 Brazil. Has a substantial chemical and biological pharmaceutical sector. Nortec Quimica and Fiocruz are potential research targets. The draft identifies benznidazole, benzodiazepines, bupivacaine, prilocaine, esketamine, ibuprofen, dexamethasone, paclitaxel, fluorouracil, etoposide, simvastatin, prednisone, omeprazole, and insulin glargine-related production for further verification. Claims about current manufacturing location, commercial scale, export availability, and the establishment of a first regional insulin glargine API plant must be supported by current primary-source documentation. The statement that Brazil imports approximately 90% of the APIs used by its pharmaceutical industry should not be treated as verified without a defined year, denominator, methodology, and authoritative source. 16.3 Argentina. Has pharmaceutical and biotechnology capabilities. Triquim S.A. and Argentine biotechnology producers are potential sources or research targets. The investigation includes remifentanil, benfotiamine, bosentan, imiquimod, meglumine antimoniate, rituximab, bevacizumab, interferon, erythropoietin, and growth hormone. Each requires separate verification of current manufacturer, site, approved product status, export permissions, and availability in the requested form and grade. Claims about the first Latin American biosimilar monoclonal antibodies and the commercial status of biotechnology products require dated, product-specific evidence. 16.4 Colombia. A candidate sourcing jurisdiction. A company or facility must be identified for each ingredient. PROQUIMES S.A. is a potential research target. No ingredient should be assigned to Colombia in a binding purchase schedule without verifying that the named facility manufactures it and is authorized to export it. 16.5 Guatemala. A candidate regional sourcing and distribution jurisdiction. Luminova Pharma is a research target for generic pharmaceutical manufacturing. Manufacturing finished generics does not establish production of the underlying APIs. Each API must be verified by product, facility, regulatory status, and documentation. 16.6 Source-country determination. The source country in the final schedule must refer to the actual API manufacturing site, not the seller's headquarters, distributor address, port of shipment, or repackaging country. No supplier is a confirmed source until the following are obtained and reviewed: - Legal manufacturer name and manufacturing address. - Product-specific technical specification. - Current production and export confirmation. - Applicable regulatory registration or authorization. - Quality documentation. - Written price and capacity quotation. - Verification that the proposed import pathway is lawful. ====================================================================== PART IV - PROPOSED PRODUCT SCHEDULE ====================================================================== 17. SCOPE OF THE CANDIDATE API SCHEDULE A preliminary list of 38 candidate ingredients across eight categories. It is a sourcing-development schedule, not a representation that all are currently available from the countries listed. Source-country assignments remain subject to supplier verification. Antibiotics: Amoxicillin; Ampicillin; Cephalexin monohydrate; Gentamicin sulfate; Lincomycin hydrochloride; Chloramphenicol. Proposed jurisdictions: Mexico; other countries only after verification. Antiparasitic: Benznidazole; Meglumine antimoniate. Brazil; Argentina, subject to verification. Central nervous system: Methylphenidate hydrochloride; Phenytoin; Sodium phenytoin; Diazepam; Clonazepam; Bromazepam. Mexico; Brazil, subject to verification. Anesthetics and analgesics: Bupivacaine; Prilocaine; Esketamine; Remifentanil; Ibuprofen. Brazil; Argentina, subject to verification. Cardiovascular: Nicardipine; Bezafibrate; Simvastatin; Bosentan. Mexico; Brazil; Argentina, subject to verification. Oncology and steroids: Paclitaxel; Fluorouracil; Etoposide; Dexamethasone; Prednisone. Brazil; Mexico, subject to verification. Other small molecules: Omeprazole; Folic acid; Benfotiamine; Imiquimod. Mexico; Brazil; Argentina, subject to verification. Biologics and biotechnology-derived products: Rituximab; Bevacizumab; Interferon; Erythropoietin; Growth hormone; Insulin glargine. Argentina; Brazil, subject to product-specific verification. Schedule count: 38 candidate ingredients. Classification note: rituximab, bevacizumab, interferons, erythropoietin, growth hormone, and insulin glargine are not interchangeable with conventional small-molecule APIs. Regulatory status, manufacturing, quality controls, handling, and product-approval requirements differ. The final contract must distinguish chemical APIs from biotechnology-derived substances and biological products. "Off-patent" must be verified at the relevant level; patent status varies by jurisdiction, formulation, process, indication, and product, and off-patent status does not remove regulatory, quality, import, or procurement requirements. 17.1 Controlled-substance review. The initial draft marks diazepam, clonazepam, bromazepam, methylphenidate, remifentanil, and esketamine as controlled substances. This is not a final legal classification for every ingredient, formulation, salt, jurisdiction, or transaction. The final schedule must identify the applicable U.S. Controlled Substances Act schedule, DEA registration category, import authorization, quota requirements where applicable, and additional restrictions. No controlled-substance transaction may proceed until requirements are confirmed with the Drug Enforcement Administration and other relevant authorities. ====================================================================== PART V - PRICING METHODOLOGY AND MINIMUM MARGIN ====================================================================== 18. PRICING FORMULA Landed cost = documented supplier cost x 1.12 Contract floor = landed cost x 1.15 Equivalently: Contract floor = documented supplier cost x 1.12 x 1.15 The resulting contract floor is 1.288 times supplier cost, a 28.8% markup on that cost. This is not a 15% gross margin on the final selling price. A 15% markup on landed cost yields a gross margin of approximately 13.04% of the selling price when landed cost is the only cost of sales. If a true minimum gross margin of 15% on selling price is intended, use: Contract floor = landed cost / 0.85. The final agreement must specify which measure applies. The schedule below preserves the original formula as a 15% markup on landed cost. 19. INDICATIVE LOW-END PRICE SCHEDULE All figures are preliminary planning estimates, not verified supplier quotations, established market prices, or binding offers. API | Supplier cost/kg | Landed cost/kg (x1.12) | Contract floor/kg (x1.15) Ibuprofen | $5.00 | $5.60 | $6.44 Folic acid | $15.00 | $16.80 | $19.32 Amoxicillin | $25.00 | $28.00 | $32.20 Ampicillin | $30.00 | $33.60 | $38.64 Cephalexin | $30.00 | $33.60 | $38.64 Chloramphenicol | $40.00 | $44.80 | $51.52 Phenytoin | $40.00 | $44.80 | $51.52 Gentamicin sulfate | $100.00 | $112.00 | $128.80 Simvastatin | $100.00 | $112.00 | $128.80 Lincomycin hydrochloride | $150.00 | $168.00 | $193.20 Omeprazole | $150.00 | $168.00 | $193.20 Prednisone | $300.00 | $336.00 | $386.40 Fluorouracil | $300.00 | $336.00 | $386.40 Diazepam* | $300.00 | $336.00 | $386.40 Clonazepam* | $800.00 | $896.00 | $1,030.40 Bupivacaine | $800.00 | $896.00 | $1,030.40 Dexamethasone | $1,000.00 | $1,120.00 | $1,288.00 Methylphenidate hydrochloride* | $2,000.00 | $2,240.00 | $2,576.00 Etoposide | $3,000.00 | $3,360.00 | $3,864.00 Paclitaxel | $10,000.00 | $11,200.00 | $12,880.00 * Preliminary controlled-substance flag; final classification and authorization must be verified. The calculations are arithmetically consistent with the stated formula. The underlying supplier-cost estimates have not been independently established as current, commercially available prices. 20. PRICING FOR REMAINING CANDIDATE APIs For benznidazole, bromazepam, prilocaine, esketamine, remifentanil, bezafibrate, nicardipine, bosentan, imiquimod, benfotiamine, meglumine antimoniate, and all biotechnology-derived ingredients, price is calculated from a current written supplier quotation. Each purchase order must attach: - The supplier's dated quotation. - The quoted product grade and specification. - The manufacturing-site address. - Currency, quantity, minimum order, and validity period. - Freight and insurance assumptions. - Customs, testing, handling, and storage charges. - Applicable import authorization and permit costs. - The agreed margin or markup calculation. No ingredient may be priced from an unverified estimate where a current quotation is required. 21. LANDED-COST EXCLUSIONS AND COMMERCIAL CONTROLS The 12% allowance is a proposed commercial assumption for freight, insurance, customs clearance, and lot testing. Actual costs may differ and must be documented. It does not automatically include costs of controlled-substance importation, customs brokerage, regulatory submissions, inspections, special handling, biological cold-chain logistics, product registration, or rejected shipments. The contract must specify whether these are included in the floor price or billed separately. No order should be accepted below the agreed minimum pricing threshold unless an authorized written amendment changes the terms. ====================================================================== PART VI - REGULATORY, QUALITY, AND PROCUREMENT COMPLIANCE ====================================================================== 22. FDA REQUIREMENTS FOR IMPORTED APIs APIs imported or offered for import into the United States must comply with the Federal Food, Drug, and Cosmetic Act and Title 21 CFR. FDA guidance identifies requirements that may include foreign-establishment registration, drug listing, labeling, and CGMP compliance, depending on the ingredient, intended use, import pathway, and circumstances. Official reference: https://www.fda.gov/drugs/human-drug-imports/importing-active-pharmaceutical-ingredients General requirements: https://www.fda.gov/drugs/human-drug-imports/general-requirements-importing-human-drugs The final contract must not assume registration alone authorizes every product for import or distribution. Some products require an approved drug application or another lawful pathway. 23. QUALITY ASSURANCE AND LOT ACCEPTANCE Each shipment must include product-specific quality documentation: - Manufacturer-issued certificate of analysis. - Lot or batch identification. - Identity, strength, purity, and relevant impurity results. - Applicable USP, European Pharmacopoeia, or contractually accepted specifications. - Testing documentation from a qualified laboratory where required. - Manufacturing and expiry or retest information. - Storage, transport, and handling instructions. - Traceability records and deviation documentation. A certificate of analysis does not by itself establish full regulatory compliance. Testing methods, laboratory qualification, specifications, and acceptance criteria must be defined in the quality agreement. The contract must provide for quarantine, rejection, investigation, replacement, refund, recall cooperation, and cost allocation for nonconforming lots. 24. CONTROLLED SUBSTANCES AND DEA REQUIREMENTS Before importing any controlled substance, the parties must establish registration, import-permit, quota, reporting, security, and recordkeeping requirements. Official reference: https://www.deadiversion.usdoj.gov/quotas/quota-apps.html The final schedule must not presume that every asterisked ingredient is subject to the same quota or permit rules. Classification and requirements must be confirmed per substance and transaction. All approvals must be obtained before shipment, and permit and quota costs allocated explicitly in the contract. 25. BIOLOGICAL PRODUCTS AND BIOTECHNOLOGY-DERIVED INGREDIENTS The biological portion requires separate regulatory assessment. A biological active substance is not automatically eligible for import or distribution because a related product is marketed abroad or a patent has expired. Depending on intended use, the pathway may involve a biologics license application, another approval, or a lawful investigational or other pathway. FDA's general guidance describes the role of NDA, ANDA, IND, and BLA requirements. The final contract must distinguish an API-only transaction from importation or distribution of a finished biological drug product, and determine classification, authorization, cold-chain requirements, analytical comparability, sterility or contamination controls, and other quality obligations for each product. 26. U.S. GOVERNMENT PROCUREMENT No U.S. government agency is a party to this proposal until it accepts a legally valid procurement instrument executed by an authorized contracting officer. The final agreement must identify the agency, solicitation or contract number, appropriation or funding authority, scope, quantity, delivery schedule, inspection requirements, payment terms, procurement clauses, and dispute procedures. Procurement must comply with the Federal Acquisition Regulation, agency supplements, competition requirements, domestic-preference provisions, country-of-origin restrictions, sanctions, and other applicable rules. The parties must verify that the proposed countries, manufacturers, products, and intermediaries are eligible. A supplier named here is not thereby eligible for award, a sole-source basis, endorsement, or a purchase obligation. ====================================================================== PART VII - PROPOSED SCIENTIFIC AND BIOLOGICAL INFRASTRUCTURE ====================================================================== 27. CALIFORNIA HIGH DESERT AND INLAND EMPIRE SITE FRAMEWORK Preliminary locations in San Bernardino County for scientific exploration, combination development, biological research support, and infrastructure planning: - Apple Valley - Victorville - Big Bear Lake - Silverwood Lake - Spring Valley Lake - Mojave Narrows Regional Park - Jess Ranch Fish Hatchery, Apple Valley These are candidate geographic references, not confirmed or authorized facilities. Appearing in this document designates no property, park, lake, hatchery, or laboratory as an approved Fiveo1 operating site. Use requires confirmation of ownership, operator permission, zoning, land-use restrictions, environmental requirements, permits, and applicable research or animal-care approvals. 27.1 Scientific exploration and combination development. Potential activities include nonclinical research, analytical testing, formulation feasibility, materials characterization, biological process development, and evaluation of supporting infrastructure, subject to approvals and facilities. Any work involving human biological material, transplantation, animals, genetically modified organisms, pathogens, regulated biological agents, or clinical applications must undergo legal, ethical, biosafety, and institutional review first. 27.2 Jess Ranch Fish Hatchery. Identified as a candidate research reference because of its association with aquaculture. Claims about on-site production, vaccination, species, current operations, and suitability require confirmation from the operator and authorities. An aquaculture facility is not automatically suitable or authorized for pharmaceutical manufacturing, transplantation research, clinical research, or other regulated biological activities. 27.3 Site approval requirements. Before designating any site, Fiveo1 must document: - Owner and operator. - Exact physical address and parcel. - Written permission or lease. - Planning and environmental approvals. - Permitted research and operational activities. - Required laboratory, biosafety, and quality systems. - Waste management and emergency procedures. - Required insurance and professional oversight. - Funding and responsible operating entity. No activity is authorized by this proposal alone. ====================================================================== PART VIII - GOVERNMENT, LEGISLATIVE, REGULATORY, AND MUNICIPAL CONTACTS ====================================================================== Contact information and officeholders should be rechecked on official websites immediately before sending or executing any document. A public contact listing is not evidence of consent, sponsorship, or contract approval. 28. CALIFORNIA ASSEMBLY DISTRICT 69 The official California State Assembly page identifies Josh Lowenthal as the Assembly Member for District 69 in the information retrieved for this document. Official page: https://www.assembly.ca.gov/assemblymembers/69 Sacramento mailing: California State Assembly, P.O. Box 942849, Sacramento, CA 94249-0069 Capitol office: 1021 O Street, Suite 8320, Sacramento, CA 95814. Tel: (916) 319-2069 District office: 3777 Long Beach Boulevard, Suite 260, Long Beach, CA 90807. Tel: (562) 366-2769 The district office is a relevant channel for submitting a proposal or requesting information about legislative procedures. Its inclusion does not mean the Assembly Member endorses this proposal or that it has been introduced as a bill. 28.1 Legislative submission. The proponent may submit this document and request guidance on: - Whether the proposal suits state legislation, federal legislation, or a commercial procurement process. - Which committee or agency has jurisdiction. - Whether a formal bill request or legislative counsel review is appropriate. - Which procurement, pharmaceutical, public-health, or economic-development authorities should be consulted. A proposal must not be represented as an enacted bill or official Assembly measure until formally introduced and assigned a bill number. 29. CITY OF AVALON - CITY HALL AND CITY COUNCIL Physical address: City Hall, 410 Avalon Canyon Road, Avalon, CA 90704 Mailing address: P.O. Box 707, Avalon, CA 90704 Main telephone: (310) 510-0220 Public comments and questions: ask@cityofavalon.com (as supplied; verify the domain against the official city site, which is https://www.cityofavalon.gov/) Council meetings: first and third Tuesday of each month at 5:00 p.m., City Hall Council Chambers. Website: https://www.cityofavalon.gov/ City Council: https://www.cityofavalon.gov/216/City-Council City Manager's Office: https://www.cityofavalon.gov/159/Administration-City-Managers-Office City Clerk: https://www.cityofavalon.gov/161/City-Clerk Staff directory: https://www.cityofavalon.gov/m/directory The city's directory page for each councilmember includes an "Email" link, the most reliable route for contacting them directly. Individual email links are provided through the directory rather than published as plain-text addresses. 29.1 Avalon City Council contacts - Ann Marshall, Mayor. Tel: (310) 339-2935. Email: amarshall@cityofavalon.gov - Michael Ponce, Mayor Pro Tem. Email: mponce@cityofavalon.gov - Lisa Lavelle, Councilmember. Email: llavelle@cityofavalon.gov - Donna Lopez, Councilmember. Email: dlopez@cityofavalon.gov - Yesenia De La Rosa, Councilmember. Email: ysdelarosa@cityofavalon.gov - David Maistros, City Manager. Main office (310) 510-0220, ext. 122 - Gabrielle Morones, City Clerk. Main office (310) 510-0220, ext. 119 The City of Avalon is a municipal government contact, not the proposed buyer or regulator for the federal API procurement program. 30. FEDERAL PHARMACEUTICAL AND PROCUREMENT AUTHORITIES 30.1 U.S. Food and Drug Administration. Subject: API import compliance, establishment registration, drug listing, product approval, quality requirements. - https://www.fda.gov/drugs/human-drug-imports/importing-active-pharmaceutical-ingredients - https://www.fda.gov/drugs/human-drug-imports/general-requirements-importing-human-drugs - https://www.fda.gov/industry/importing-fda-regulated-products/importing-human-drugs 30.2 Drug Enforcement Administration. Subject: controlled-substance registration, import authorization, quota, compliance. - https://www.deadiversion.usdoj.gov/ - https://www.deadiversion.usdoj.gov/quotas/quota-apps.html The general contact route does not substitute for product-specific authorization. 30.3 U.S. government contracting. Subject: agency identification, opportunities, solicitations, authorized contracting officers. - https://sam.gov/ - https://www.acquisition.gov/far The buyer and solicitation must be identified before a government contract can be completed. Fiveo1 should use the agency's official procurement channels and verify the contracting officer's authority. 31. FIVEO1 SUPPLIER CONTACT Fiveo1, P.O. Box 312786, Avalon, California 90704, Santa Catalina Island, California. Proposed representative: Evan Winter. No telephone number or email address for Fiveo1 is supplied; none is invented here. Any public-facing contact details must be provided and verified by Fiveo1 before distribution. ====================================================================== PART IX - GENERAL COMMERCIAL TERMS ====================================================================== 32. Minimum price and margin. The pricing method applies the agreed supplier-cost and landed-cost assumptions to the applicable purchase order. No sale proceeds below the contract floor in the executed agreement. Markup on landed cost must be distinguished from gross margin on selling price. Any change to the formula must be documented in writing. 33. Supplier quotations. All final purchase orders must include current written quotations from the actual manufacturer or authorized supplier, with product identity, grade, specifications, quantity, price, lead time, shipping terms, and validity. Indicative estimates here must be replaced by documented quotations before a binding transaction. 34. Source countries and traceability. Proposed jurisdictions: Mexico, Brazil, Argentina, Colombia, Guatemala. The actual manufacturing country and site must be identified for every lot. Origin declarations, export documents, shipping records, and manufacturing documentation must be consistent. No ingredient is assigned to a country solely because a distributor or trading company is located there. 35. Quality. Products must meet specifications in the quality agreement and all legal requirements. The parties must establish lot acceptance criteria, testing responsibilities, record retention, audit rights, change control, deviations, complaint handling, recall cooperation, and liability for defective or misrepresented materials. 36. Delivery and risk of loss. Delivery terms, destination, shipping method, insurance, customs responsibilities, inspection, and title and risk transfer must be stated in each purchase order. The initial proposal contemplates transfer of title and risk upon delivery to the designated U.S. government receiving facility; this must be reconciled with the final delivery term, applicable law, and government contract clauses. 37. Payment. Payment terms must be set by the executed agreement or purchase order. No payment schedule, government funding commitment, or credit arrangement is created by this proposal. 38. Rejection, termination, and liability. The final agreement should establish: - Rejection of nonconforming or improperly documented goods. - Replacement, refund, or other remedies. - Responsibility for testing, detention, storage, and disposal. - Product recall and adverse-event cooperation. - Indemnification and insurance. - Termination for default, regulatory failure, or convenience where permitted. - Dispute resolution and governing law. - Records retention and audit rights. 39. Governing law. The original proposal specifies California law and applicable federal procurement regulations. The final agreement must be reviewed to determine the appropriate governing-law clause, federal procurement terms, jurisdiction, and dispute procedures. A California-law clause cannot displace mandatory federal statutes, federal procurement requirements, or other applicable law. ====================================================================== PART X - EXECUTION CONDITIONS AND REPRESENTATIONS ====================================================================== 40. CONDITIONS PRECEDENT TO A BINDING CONTRACT No binding API purchase or government supply obligation should arise until all applicable conditions are satisfied: - Identification of the buyer and authorized contracting officer. - Confirmation of the supplier's legal identity and capacity. - Product-by-product manufacturer and site verification. - Written commercial quotations. - FDA registration, listing, and product-pathway verification. - Controlled-substance authorization where required. - Biological-product pathway determination where applicable. - Quality agreement and lot-acceptance criteria. - Import, export, customs, and transportation arrangements. - Funding, purchase order, and delivery authorization. - Final review of procurement clauses and governing law. 41. REPRESENTATIONS AND LIMITATIONS This proposal is a statement of intended objectives and a preliminary commercial framework. It does not represent that: - Fiveo1 has been awarded a U.S. government contract. - Any government agency has accepted or endorsed the proposal. - Every named company manufactures the attributed ingredients at a particular site. - The preliminary supplier prices are current market quotations. - The listed biological products are automatically eligible for import. - All candidate APIs are legally unrestricted or available for export. - The identified scientific sites have approved the proposed activities. - The program has received legislative approval, appropriations, or regulatory authorization. All such matters require documentary verification and, where applicable, formal approval. ====================================================================== PART XI - SIGNATURE AND SUBMISSION ====================================================================== 42. PROPOSED SUPPLIER SIGNATURE Fiveo1 Represented by: Evan Winter Mailing address: P.O. Box 312786, Avalon, California 90704 Signature: ____________________________________ Date: _________________________________________ 43. PROPOSED GOVERNMENT BUYER SIGNATURE United States Government Agency: ____________________________________ Agency and contracting office: ________________________________________ Authorized contracting officer: _______________________________________ Solicitation or contract number: ______________________________________ Signature: ____________________________________ Date: _________________________________________ The buyer's signature section is for completion only if an authorized agency enters into a valid contract. It does not imply that any agency is currently a party to this proposal. ====================================================================== APPENDIX A - SOURCE-SIDE LOCATION AND DEVICE METADATA (OPTIONAL) ====================================================================== Note: This appendix is personal technical data. It is recommended that it be REMOVED from any copy sent by postal mail or distributed to third parties. The initial draft included the following submitted metadata: - IP address: 190.143.186.107 - Reported network: Telecomunicaciones de Guatemala / Claro - Device description: Mozilla/5.0 (Linux; Android 10; K) AppleWebKit/537.36 (KHTML...) - Screen dimensions: Unknown - Reported coordinates: 14.738654, -91.158361 - Reported location description: Calle 15 de Febrero, Guatemala These values are retained as submitted, not independently verified. IP-to-provider attribution requires a current registration or network lookup. An IP address does not prove identity or exact location. Coordinates may originate from a device, browser, mapping service, or manual entry, and their provenance must be documented. The coordinates are consistent with the general Panajachel/Lake Atitlan area, but street-level placement requires mapping verification. Device and location data should be retained only for a defined operational purpose, with access controls, accuracy labels, and privacy safeguards. The metadata does not establish a supplier's identity, a manufacturing site, a government relationship, or the origin of a pharmaceutical ingredient. ====================================================================== FINAL STATEMENT ====================================================================== Fiveo1 proposes a framework for distinguishing factual claims, legal classifications, moral judgments, public opinion, political authority, and the evaluation of consequences while developing a verifiable pharmaceutical API sourcing and procurement initiative. The framework requires that disagreement not be mistaken for proof of error, opposition not be mistaken for proof of harm, public support not be mistaken for proof of factual accuracy, and legal status not be mistaken for a complete moral assessment. The pharmaceutical initiative applies the same principle operationally: country-level capability is not proof of product availability; an indicative price is not a verified quotation; an identified agency is not a contracting party; and a proposed activity is not an authorized activity. The program must proceed through evidence, supplier verification, applicable legal standards, quality controls, transparent pricing, and authorized procurement procedures. Respectfully submitted, FIVEO1 Evan Winter P.O. Box 312786 Avalon, California 90704 Santa Catalina Island, California